ω-3脂肪酸或可有效改善癌症患者的生活质量及对疗法的反应

  近日，一项刊登于国际杂志the Journal of Parenteral and Enteral Nutrition (JPEN)上的研究论文中，来自莱斯特大学信托保健附属医院的研究人员通过研究表示，将ω-3脂肪酸类添加到抗肿瘤药物中或可帮助改善癌症患者对疗法的反应以及生活质量。
  文章中研究者对50名患恶性胰腺癌的患者进行了研究，患者每周被给予1000mg的吉西他滨，随后给予患者外加最多100g的富含ω-3的脂肪乳，持续三周，随后患者休息一周；上述治疗过程一直持续6个循环，在这期间存在患者病情进展、不可接受的毒性、病人请求以及死亡等情况发生。
  研究表明，被研究患者的生活质量明显得到了改善，同时其对药物的反应活性、疾病的稳定率以及肝脏转移程度都相应地降低了。
  这项研究首次利用ω-3脂肪酸同癌症化疗制剂进行结合来检测联合疗法对于癌症患者的作用，研究者认为本文的研究成果非常振奋人心，后期他们还将开展随机的III期临床试验，进行更多深入的研究及调查。（转化医学网360zhyx.com）
  以上为转化医学网原创翻译整理，转载请注明出处和链接！
转化医学网推荐的原文摘要：

A Randomized Controlled Trial Investigating the Effects of Parenteral Fish Oil on Survival Outcomes in Critically Ill Patients With Sepsis:A Pilot Study
JPEN J Parenter Enteral Nutr    doi: 10.1177/0148607113518945
Thomas C. Hall, MRCS1 Dilraj K. Bilku, MRCS1 Dhya Al-Leswas, MRCS1 Christopher P. Neal, PhD1 Cindy Horst, FRCA1 Jill Cooke1 Matthew S. Metcalfe, MD Ashley R. Dennison, MD1
Introduction: Death from sepsis in the intensive care unit (ITU) is frequently preceded by the development of multiple organ failure as a result of uncontrolled inflammation. Treatment with ω-3 has been demonstrated to attenuate the effects of uncontrolled inflammation and may be clinically beneficial. Method: A randomized control trial investigating the effects of parenteral ω-3 was carried out. Consecutive patients diagnosed with sepsis were entered into the study and randomized to receive either parenteral ω-3 or standard medical care only. The primary outcome measure was a reduction in organ dysfunction using the Sequential Organ Failure Assessment (SOFA) score as a surrogate marker. The secondary outcome measures were mortality, length of stay, mean C-reactive protein (CRP), and days free of organ dysfunction/failure. Results: Sixty patients were included in the study. The baseline demographics were matched for the two cohorts. Patients treated with parenteral ω-3 were associated with a significant reduction in new organ dysfunction (Δ-SOFA 2.2 ± 2.2 vs. 1.0 ± 1.5, P = .005 and maximum-SOFA 10.1 ± 4.2 vs. 8.1 ± 3.2, P = .041) and maximum CRP (186.7 ± 78 vs. 141.5 ± 62.6, P = .019). There was no significant reduction in the length of stay between cohorts. Patients treated with ω-3 in the strata of less severe sepsis had a significant reduction in mortality (P = .042). Conclusion: The treatment of critically ill septic patients with parenteral ω-3 is safe. It is associated with a significant reduction in organ dysfunction. It may be associated with a reduction in mortality in patients with less severe sepsis.